Soliris is a complement inhibitor indicated for: • The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis . • The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. The effectiveness of Soliris in aHUS is based on the effects on thrombotic microangiopathy (TMA) and renal function.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Soliris (eculizumab) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Soliris (eculizumab) medicine cost price in India.
The order for Soliris (eculizumab) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Eculizumab, sold under the trade name Soliris among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death.
Soliris® (eculizumab) Concentrated solution for intravenous infusion Initial U.S. Approval: 2007
Generic Name: eculizumab
300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Soliris (eculizumab) on prescription and Import License in Patient's Name only.
For overseas patients, Soliris (eculizumab) can be made available in Send your enquiry to find Soliris (eculizumab) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For Soliris (eculizumab) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
ADDING MULTIMEDIA Alexion Receives FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 (AQP4) Antibody Positive For More Details
FDA Greenlights Alexion’s Soliris for Rare Autoimmune Disease For More Details